glp-1 rheumatoid arthritis study Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity? GLP-1 Agonists In Arthritis And
Description
Tirzepatide , a dual GLP-1/GIP receptor agonist, has been approved by NICE for type 2 diabetes management
Trautmann M
Originally developed for type 2 diabetes, these drugs are a prime example of successful drug repurposing, their unexpected benefits on weight loss and cardiovascular outcomes quickly took center stage, catapulting them into a broader spotlight
Could be reduced with strong PBPK models
This is the Phase 3 dose typically reached during weeks 9 through 12 of the standard escalation protocol
Lancet, 2021
